Drug profile

The FDA adverse-event record for Milbemycin And Spinosad

12 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Milbemycin And Spinosad. See the species affected, top reactions, and outcomes below.

12
adverse-event reports
25.0%
death-coded share
Dog
most-reported species
6
Lack of efficacy (endoparasite) - heartworm - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
3
Deaths Reported
25.0%
Death Rate

Active Ingredients

Milbemycin And Spinosad

Administration Routes

UnknownOral

Species Affected

Dog 12

Most Affected Breeds

Spaniel (unspecified) 3
Shepherd Dog - German 2
Retriever - Labrador 2
Terrier - Bull - American Pit 2
Mastiff 1
Collie - Border 1
Weimaraner 1

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 6
Anaemia NOS 4
Otitis externa 3
Hyperkalaemia 3
Thrombocytosis 3
Emesis (multiple) 3
Bloody diarrhoea 3
Lethargy (see also Central nervous system depression in Neurological) 3
Elevated blood urea nitrogen (BUN) 3
Monocytosis 3
Elevated serum alkaline phosphatase (ALP) 3
Ascites 3

Outcome Breakdown

Ongoing
6 (50.0%)
Euthanized
3 (25.0%)
Recovered/Normal
2 (16.7%)
Outcome Unknown
1 (8.3%)

Milbemycin And Spinosad Adverse Event Insights

12 reports name Milbemycin And Spinosad; 3 recorded a death outcome (25.0% of reported events, not a population-level mortality rate). Active ingredient: Milbemycin And Spinosad. Administration routes: Unknown, Oral.

By species: Dog (12 reports). By breed: Spaniel (unspecified) (3), Shepherd Dog - German (2), Retriever - Labrador (2).

Leading clinical signs: Lack of efficacy (endoparasite) - heartworm (6), Anaemia NOS (4), Otitis externa (3), Hyperkalaemia (3). Outcome, 12 coded reports: Ongoing leads at 50.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.